Get the app
US › Healthcare

Kalaris Therapeutics, Inc. (KLRS)

US · Healthcare · Biotechnology

$3.16-0.63%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-11.5M
EPS
$-0.48
EPS estimate
$-0.50

EPS came in at -0.48 against a street estimate of -0.50 — a beat of 4.0%.

Key statistics

Market cap
$80.5M
Forward P/E
0.0
P/B
1.40
Book value
$2.42
EPS (TTM)
$-1.90
52-week high
$11.88
52-week low
$3.03
50-day MA
$4.06
200-day MA
$6.37

Analyst view

Analysts rate Kalaris Therapeutics, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $18.71.

Shareholding

Insiders
8.81%
Institutions
75.72%

Largest institutional holders

FundStake
Samsara BioCapital, LLC54.11%
RTW INVESTMENTS, LLC5.46%
Alyeska Investment Group, L.P.2.41%
Siren, L.L.C.1.83%
Ikarian Capital, LLC1.51%
Kalehua Capital Management LLC1.14%
Vanguard Capital Management, LLC1.07%
The Goldman Sachs Group Inc0.46%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kalaris Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.